文献速递病毒性肝炎

丙肝患者及高危人群对长效治疗方案的偏好调查

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该横断面调查在9国28个中心对1457名HCV感染者或高危者进行43题问卷,评估对长效治疗策略的相对兴趣。感染者中37.7%最偏好注射剂,5.6%偏好植入剂,6%偏好胃滞留装置,50.8%最偏好每日1-3片口服药。直接比较时,注射偏好与年龄、地点和既往治疗史相关,植入偏好与女性和年轻年龄相关。高危未感染者中49.5%认为注射比口服药更强效,34.7%偏好注射。

要点

  • HCV感染者中约半数仍最偏好每日口服药,但37.7%最偏好注射剂。
  • 注射偏好与年龄、地点、既往HCV治疗史相关,与性别无关。
  • 植入剂偏好与女性和较年轻年龄相关。

核心结论

  • 长效HCV治疗具有较高可接受性,相当一部分少数人群甚至可能偏好长效治疗而非口服药。
  • 长效HCV治疗可能有助于全球消除丙型肝炎的努力。

研究设计与样本

  • 横断面43题问卷调查,在9个国家28个中心对1457名HCV感染者或高危者进行。

主要发现

  • HCV阳性参与者中37.7%最偏好注射剂,5.6%偏好植入剂,6%偏好胃滞留装置,50.8%最偏好每日1-3片口服药。
  • 与口服药直接比较,注射偏好差异见于年龄(P<.001)、地点(P<.001)和既往HCV治疗史(P=.005),性别无差异。
  • 与口服药比较,植入剂偏好更高见于女性(P=.01)和较年轻成人(每5岁P=.01)。
  • 无HCV参与者中49.5%认为注射比口服药更强效,34.7%偏好注射而非口服药。
  • 既往接受过注射药物的高危参与者中123/137(89.8%)表示未来愿意接受注射。

临床怎么用

  • 临床沟通HCV治疗选择时可考虑部分患者对长效注射方案的接受度较高。
  • 针对女性、年轻成人及既往注射用药者可关注其对植入剂或注射剂的偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whereas safe, curative treatments for hepatitis C virus (HCV) have been available since 2015, there are still 58 million infected persons worldwide, and global elimination may require new paradigms. We sought to understand the acceptability of approaches to long-acting HCV treatment. METHODS: A cross-sectional, 43-question survey was administered to 1457 individuals with or at risk of HCV at 28 sites in 9 countries to assess comparative interest in a variety of long-acting strategies in comparison with oral pills. RESULTS: Among HCV-positive participants, 37.7% most preferred an injection, 5.6% an implant, and 6% a gastric residence device, as compared with 50.8% who stated they would most prefer taking 1-3 pills per day. When compared directly to taking pills, differences were observed in the relative preference for an injection based on age (P<.001), location (P<.001), and prior receipt of HCV treatment (P=.005) but not sex. When an implant was compared with pills, greater preference was represented by women (P=.01) and adults of younger ages (P=.01 per 5 years). Among participants without HCV, 49.5% believed that injections are stronger than pills and 34.7% preferred taking injections to pills. Among those at-risk participants who had received injectable medications in the past, 123 of 137 (89.8%) expressed willingness to receive one in the future. CONCLUSIONS: These data point to high acceptability of long-acting treatments, which for a substantial minority might even be preferred to pills for the treatment of HCV infection. Long-acting treatments for HCV infection might contribute to global efforts to eliminate hepatitis C.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Weld ED, Astemborski J, Kirk GD, et al. Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. Clin Infect Dis. 2022. PMID: 34699587. doi:10.1093/cid/ciab913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。